Medical device startup MyoScience has added Robert Grant to its board. Grant is the former CEO and president of Bausch & Lomb Surgical and a former president of Allergan Medical, the maker of Botox. Redwood City, Calif.-based MyoScience is developing procedures aimed at preventing and reducing facial wrinkles. MyoScience is backed by investors including De Novo Ventures, Accuitive Medical Ventures, Nexus Medical Partners, Saratoga Ventures and Medicis Capital.
MyoScience, Inc. today announced that Robert E. Grant, CEO and President of Bausch & Lomb Surgical and former President of Allergan Medical, Inc., maker of BOTOX® Cosmetic, was elected to the MyoScience board of directors. Grant joined Bausch and Lomb in August of 2010 after serving as President of Allergan Medical from 2006 to 2010 where he was responsible for BOTOX Cosmetic, JUVEDERM®, Latisse® and LAP-BAND®, making Allergan Medical the world leader in products for aesthetic medicine. Prior to joining Allergan Medical, he served as Chairman (Acting), CEO and President of BIOLASE Technology, Inc, a publicly traded cosmetic dentistry company. Additionally, he currently serves on the boards of directors of Technolas Perfect Vision, GmbH, Acufocus, Inc., OCTANe, and the Henry Samueli School of Engineering at the University of California, Irvine.
“Robert Grant has a strong background in executive management and marketing combined with an exceptionally broad network and deep experience in the field of aesthetics. This very relevant experience, combined with his critical insight into the worldwide facial aesthetics market will greatly benefit MyoScience as we position and initiate commercial efforts of our patented cold-based, CRYONEUROMODULATION™ technology for treating dynamic facial wrinkles,” said Bob Curtis, MyoScience CEO.
“MyoScience has a highly differentiated and patented approach for treating dynamic facial wrinkles without the use of therapeutic pharmaceutical or biologic agents. There is presently a significant unserved group of people worldwide who are averse to neurotoxins and who have not sought treatment for their dynamic facial wrinkles. For the first time, thanks to MyoScience, these patients will have an alternative to the injection of neurotoxins,” said Robert Grant. “I look forward to working with this dynamic team and the board to make MyoScience’s unique minimally invasive cold-based technology successful in the future.”
About MyoScience Inc.
MyoScience, Inc., founded in 2005 with headquarters in Redwood City, California, is a privately held, pre-commercial stage company.
MyoScience is developing an innovative medical device and minimally invasive procedure to deliver a precisely controlled subcutaneous cooling effect to relax facial muscles that cause dynamic facial wrinkles to form. The patented CRYONEUROMODULATION™ procedure would be expected to offer specialty aesthetic physicians an important new alternative treatment for the very large group of patients who are averse or resistant to neurotoxins, such as BOTOX® Cosmetic or Dysport®.
The MyoScience technology has been cleared by the U.S. FDA for general surgical use and for the treatment of peripheral nerves for relieving pain. The MyoScience CRYONEUROMODULATION™ technology is not cleared for use in the U.S. for aesthetic applications. It is currently in clinical trials for reducing dynamic facial wrinkles (such as frown lines between the brows, forehead lines, and crow’s feet) in the upper face.
MyoScience is backed by an experienced group of medical technology venture capital investors, including: De Novo Ventures, Accuitive Medical Ventures, Nexus Medical Partners, Saratoga Ventures, and Medicis Capital GmbH.